Biora Therapeutics, Inc.

Biora Therapeutics, Inc.

OOTC:BIORQ
0.00
USD
0.00
(0.00%)
-9.71EPS

Important Dates

Biora Therapeutics, Inc.'s next confirmed earnings release is scheduled for November 16, 2026.

Earnings Date11/16/2026

Share Statistics

As of September 30, 2024, Biora Therapeutics, Inc. has 3.68M shares outstanding.

Shares Outstanding3.68M

Financial Position

As of September 30, 2024, Biora Therapeutics, Inc. maintains a current ratio of 0.05, meaning it holds 0.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -37.18, indicating conservative leverage, while an interest coverage ratio of -8.25 demonstrates limited ability to service its debt obligations.

Current Ratio0.05
Quick Ratio0.03
Debt / Equity-37.18
Debt / EBITDA-0.66
Interest Coverage-8.25

Financial Efficiency

USD

These figures cover the twelve months ended September 30, 2024. Return on assets (ROA) is negative at -128.19, reflecting losses generated across the asset base. The company generates approximately 15,379.31 in revenue per employee across its workforce of 58.00, a quick read on workforce productivity versus industry peers.

Return on Assets (ROA)-128.19
Revenue Per Employee15,379.31
Employee Count58.00

Taxes

USD

Over the twelve months ended September 30, 2024, Biora Therapeutics, Inc. recorded an income tax benefit of -158,000.00 rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -35.73M and -31.54M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax-158,000.00

Stock Price Statistics

USD

As of the close on November 10, 2026, Biora Therapeutics, Inc.'s stock has gained approximately 0.00% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.06.

200-Day Moving Average0.06

Income Statement

USD

Over the twelve months ended September 30, 2024, Biora Therapeutics, Inc. generated 892,000.00 in revenue and converted that into -31.54M in net income, yielding earnings per share of -9.71. EBITDA reached -60.43M, while operating income came in at -60.87M.

Revenue892,000.00
Operating Income-60.87M
Pretax Income-35.73M
Net Income-31.54M
EBITDA-60.43M
EBIT-60.87M
Earnings Per Share (EPS)-9.71

Balance Sheet

USD

As of September 30, 2024, Biora Therapeutics, Inc. holds 3.20M in cash and equivalents against 39.65M in total debt, resulting in a net debt position of 35.40M. Total book value stands at -106.63M, with working capital of -114.56M providing operational flexibility.

Cash & Cash Equivalents3.20M
Total Debt39.65M
Net Debt35.40M
Equity (Book Value)-106.63M
Book Value Per Share-28.99
Working Capital-114.56M

Cash Flow

USD

Biora Therapeutics, Inc. produced -45.92M in operating cash flow over the twelve months ended September 30, 2024. After subtracting -280,000.00 in capital expenditures, free cash flow totaled -46.20M - equivalent to -17.11 per share.

Operating Cash Flow-45.92M
Capital Expenditures-280,000.00
Free Cash Flow-46.20M
FCF Per Share-17.11

Margins

These figures cover the twelve months ended September 30, 2024. The operating margin of -6,824.33 and net profit margin of -3,535.76 provide insight into operational efficiency.

Operating Margin-6,824.33
Pretax Margin-4,005.83
Profit Margin-3,535.76
EBITDA Margin-6,774.66

Stock Splits

Biora Therapeutics, Inc.'s most recent stock split took place on October 18, 2024 with a 10:1 split ratio.

Last Split Date10/18/2024
Split Ratio10:1